MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
IMCR stock logo

IMCR

Immunocore Holdings plc

$30.83
0.52
 (1.72%)
Exchange:  NASDAQ
Market Cap:  1.563B
Shares Outstanding:  27.307M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Bahija Jallal
Full Time Employees:  493
Address: 
92 Park Drive
Abingdon
OX14 4RY
GB
Website:  https://www.immunocore.com
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company’s programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/08/09 — Q2 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue197,385.916247,983.620297,569.634
Gross Profit196,565.282242,439.599291,355.885
EBITDA-40,870.283-38,504.060387.177
Operating Income-47,203.491-56,280.019-33,737.839
Net Income-43,751.604-40,805.230-26,418.662

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets597,0011,009,5061,067,269
Total Liabilities228,158648,790686,236
Total Stockholders Equity368,843360,716381,033
Total Debt84,032432,72243,562
Cash and Cash Equivalents442,626455,731467,709

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow2,94026,061-10,712
Capital Expenditure-5,425-5,173-4,340
Free Cash Flow-2,48520,888-15,052
Net Income-43,368.781-51,087-35,514
Net Change in Cash40,15413,10511,978

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)907,927.264Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)1,174,936.428Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)1,051,704.524Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-382,311.326Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-295,429.495Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-342,213.027Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)254,314.591Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)356,391.942Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)309,280.480Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)819,109.200Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)1,059,998.170Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)948,821.437Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)6.140Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)7.080Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)5.050Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)5Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)3Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
310.333M  ?P/S
 (TTM)
: 
4.27
?Net Income
 (TTM)
: 
-51108496.83  ?P/E
 (TTM)
: 
-59.15
?Enterprise Value
 (TTM)
: 
1.17B  ?EV/FCF
 (TTM)
: 
-77.73
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-0.07  ?ROIC
 (TTM)
: 
-0.05
?Net Debt
 (TTM)
: 
-387654000  ?Debt/Equity
 (TTM)
: 
0.11
?P/B
 (TTM)
: 
4.16  ?Current Ratio
 (TTM)
: 
4.04

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate IMCR Intrinsic Value

Common questions about IMCR valuation

Is IMCR (IMCR) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for IMCR (IMCR) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is IMCR a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether IMCR trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is IMCR’s P/E ratio?

You can see IMCR’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for IMCR?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is IMCR a good long-term investment?

Whether IMCR fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

IMCR

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

1.72
Chart data temporarily unavailable.
Daily snapshot

Trading Metrics:

Open: —   Previous Close: —
Day Low: —   Day High: —
Year Low:    Year High: 
Price Avg 50:    Price Avg 200: 
Volume:    Average Volume: 
Session data unavailable

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting
Immunocore (IMCR) Upgraded to Strong Buy: Here's Why
Immunocore (IMCR) Upgraded to Strong Buy: Here's What You Should Know

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read